The result was consistent with the randomized phase III AURA trial that osimertinib showed a significant survival benefit in patients with advanced NSCLC who progressed to prior EGFR-TKIs and were T790M-positive [11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.